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Abstract
Background: There are no guidelines governing the concomitant use of recombinant human
activated protein C (rhAPC) and deep venous thrombosis/pulmonary embolism (DVT/PE)
prophylaxis in critically ill patients. It is unknown if rhAPC provides any protection against DVT/PE
in this population of patients.
Methods: Case report.
Results:  This report describes the first case of a radiographically demonstrated pulmonary
embolism occurring in a patient receiving continuous therapeutic infusion of rhAPC.
Conclusion: The administration of rhAPC alone may not be sufficient DVT/PE prophylaxis in high
risk patients. The risks associated with concomitant anticoagulation and rhAPC therapy are
unknown. Further research is necessary to determine the safest and most effective regimen for
DVT/PE prophylaxis in patients receiving rhAPC.
Background
Recombinant human activated protein C (rhAPC) has
been demonstrated to improve mortality in critically ill
patients with septic shock [1]. It is thought that rhAPC
exerts its effect via multiple mechanisms involving anti-
inflammatory, antioxidative, antiapoptotic and anticoag-
ulant pathways [2]. The anticoagulant effect of rhAPC
leads to a 2–3% incidence of severe bleeding complica-
tions in treated patients [1]. This risk has led to the general
practice of discontinuing the use of all other forms of anti-
coagulation, including deep venous thrombosis (DVT)
prophylaxis, when rhAPC is used. It is unknown what
DVT or pulmonary embolism (PE) prophylaxis is safe and
appropriate in patients receiving rhAPC. Further, it is not
known if rhAPC alone provides any protection against
DVT/PE. We present a case report of a patient who devel-
oped a new, documented PE while receiving a continuous
infusion of rhAPC.
Case presentation
A 48 year old male resident of a psychiatric institution pre-
sented to the emergency department with diarrhea, vom-
iting and decreased mental status. He had a history of
hypertension, schizophrenia, hypothyroidism and factor
XII deficiency. He was not receiving any anticoagulation
for his Factor XII deficiency at the time of presentation.
According to his emergency department record he was
febrile to 38.7 Celsius with mild abdominal distension
and tenderness on physical examination. A computed
tomographic (CT) scan of his abdomen did not demon-
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strate any intraabdominal abnormality. An empiric diag-
nosis of infectious diarrhea with dehydration was made
and the patient was discharged back to his facility on Lev-
ofloxacin and Metronidazole and intravenous fluids.
Three days later, he represented to the emergency depart-
ment with persistent diarrhea and a metabolic acidosis. A
repeat CT scan was obtained which demonstrated an ill-
defined rectosigmoid mass, but no obstruction. The pul-
monary artery was seen on the uppermost cuts of this scan
and there was no evidence of pulmonary embolus at this
time (Figure 1). Sigmoidoscopy revealed no mass or
mucosal abnormality and the patient was admitted to the
medical intensive care unit with continued broad spec-
trum antibiotics, intravenous hydration and hemody-
namic monitoring. He was hemodynamically stable.
Sequential compression devices were documented to be
in place for DVT/PE prophylaxis.
On hospital day two, the patient developed increasing
abdominal tenderness which was associated with fevers
up to 39.5 degrees Celsius and acute renal failure. Surgery
was consulted and recommended urgent operative explo-
ration. Upon exploration the patient was found to have
mesenteric venous thrombosis with a segment of ischemic
small bowel. He underwent small bowel resection and
was returned to the intensive care unit for continued
resuscitation. At this time a heparin infusion was initiated
given the patient's known factor XII deficiency and dem-
onstrated mesenteric venous thrombosis. His partial
thromboplastin time (PTT) was maintained between 60
and 80 seconds. The following day he had not improved;
he was returned to the operating room where a second
segment of ischemic bowel was discovered and further
resection was performed. The patient again returned to
the intensive care unit in critical condition requiring pres-
sor support with levophed and continued ventilatory sup-
port with a PaO2 to FiO2 ratio of 180. At this point he was
evaluated and found to be a candidate for rhAPC. This was
initiated six hours after the completion of his operation.
Due to concerns about potential bleeding complications,
the heparin infusion was discontinued when the rhAPC
was started. At the time of heparin discontinuation the
patients PTT was 82 seconds and he had no clinical evi-
dence of DVT or PE. His activated protein C level at that
time was less than 10.
Over the course of the following two days, the patient
showed significant hemodynamic improvement and pres-
sors were discontinued. By day 3 PaO2 to FiO2 ratio had
risen to over 300 and he was requiring minimal ventila-
tory support. On postoperative day 4, the patient devel-
oped acute hypoxia with increasing ventilatory
requirements. Spiral computed tomographic scan of his
chest with intravenous contrast demonstrated a large sad-
dle pulmonary embolism (Figure 2). Heparin infusion
was reinstituted and the rhAPC drip was discontinued
after 78 hours of the 96 hour course. Doppler studies of
the lower extremities and echocardiography revealed no
evidence of deep venous or mural thrombus. Subse-
quently, the patient weaned from the ventilator and was
extubated on postoperative day 8. He was transferred to a
hospital ward and oral anticoagulation was begun on
postoperative day 9. The patient was discharged on post-
operative day 13 on oral anticoagulation with an INR or
2.2.
Conclusion/discussion
Critically ill patients are known to be at high risk for the
development of DVT/PE with a rate of thromboembolic
complications ranging between 9% and 29% depending
on the specific population studied [3-6]. Multiple clinical
trials have demonstrated that DVT/PE prophylaxis
improves clinical outcomes in the critically ill [7,8]. The
Society of Critical Care Medicine guidelines for the treat-
ment of patients with sepsis currently recommends that
all critically ill patients receive DVT/PE prophylaxis with
either subcutaneous heparin or low dose low molecular
weight heparin unless otherwise contraindicated [9].
Whether administration of rhAPC should be a contraindi-
cation to the administration of DVT/PE prophylaxis with
subcutaneous or low molecular weight heparin is not
known. The PROWESS trial (Recombinant Human Acti-
vated Protein C Worldwide Evaluation in Severe Sepsis)
offers some data on this subject. Subgroup analysis of
mortality rates according to exposure to heparin in the
PROWESS trial raised the possibility of a heparin/rhAPC
drug interaction [10]. The relative risk of 28-day all-cause
mortality was increased in the group who received both
heparin and rhAPC as compared to those who received
only rhAPC. This increased relative risk of mortality was
not due to an increase in bleeding complications in the
heparin/rhAPC group, raising the possibility that heparin
might reduce the efficacy of rhAPC. Subsequent biological
data has demonstrated that heparin increases the affinity
between native APC and alpha-1-proteinase inhibitor and
a plasma protein C inhibitor, both of which decrease
native APC activity [11]. The in-vivo effect of heparin on
rhAPC binding with alpha-1-proteinase inhibitor and
plasma protein C inhibitor is not known. Further con-
founding this issue is the fact that the presence of the het-
erozygous mutation for the factor V leyden mutation does
not seem to impact the effect of rhAPC [12].
Bleeding is the most significant complication associated
with rhAPC with a 1–2% incidence of significant bleeding
complications. At the doses used for DVT/PE prophylaxis
neither subcutaneous nor low dose low molecular weight
heparin have been associated with an increased risk of
serious bleeding complications. Low dose low molecularWorld Journal of Emergency Surgery 2006, 1:23 http://www.wjes.org/content/1/1/23
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CT Angiogram obtained prior to infusion of rhAPC demonstrating no evidence of pulmonary embolism Figure 1
CT Angiogram obtained prior to infusion of rhAPC demonstrating no evidence of pulmonary embolism.World Journal of Emergency Surgery 2006, 1:23 http://www.wjes.org/content/1/1/23
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CT Angiogram obtained after 78 hours of infusion of rhAPC demonstrating a large saddle pulmonary embolism Figure 2
CT Angiogram obtained after 78 hours of infusion of rhAPC demonstrating a large saddle pulmonary embolism.World Journal of Emergency Surgery 2006, 1:23 http://www.wjes.org/content/1/1/23
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weight heparin has, however, been associated with an
increased rate of wound hematomas in post surgical
patients. It is not known if concomitant administration of
rhAPC and either subcutaneous or low dose low molecu-
lar weight heparin produces a synergistic increase on the
risk of significant bleeding complications.
It is known that the activity of native activated protein C
is diminished in critically ill patients [13]. It is also known
that patients with congenitally low levels of native protein
C activity are prone to both micro and macrovascular
thrombosis [14]. Diminished levels of native protein C
activity may play a role in the increased risk of DVT/PE
demonstrated in critically ill patients. Modulation of this
hypercoagulable state has been hypothesized to be the
primary mechanism by which rhAPC exerts its beneficial
effects. It is also thought to be this pathway that leads to
the increased bleeding risk associated with its use. What
impact this pathway has on DVT/PE risk is unclear. One
animal study has demonstrated that the administration of
rhAPC prevents thrombin induced DVT/PE in mice [15].
The ability of rhAPC to prevent the development of DV/
PE in this very high risk animal model is encouraging but
the clinical relevance of this has not been elucidated.
There are also several other confounding factors that
become relevant when dealing with the issue of rhAPC use
and concomitant DVT/PE prophylaxis in individual criti-
cally ill patients. The kinetics of native protein C activity
varies greatly between individual patients [16]. While the
activity of native activated protein C has been demon-
strated to decrease in some critically ill patients, this
decrease is not seen in every patient. Furthermore, even in
those patients who do have decreased levels of native acti-
vated protein C activity, certain patients have earlier
rebound of native protein C activity while others may
have prolonged suppression of activity. These variations
in individual native activated protein C kinetics could
lead to a wide variation of the degree of anticoagulation
produced by rhAPC administration. Further, individual
abnormalities of the coagulation cascade, whether
acquired or genetic, are being identified with increasing
frequency in the general population [17]. It follows that
these abnormalities occur with a similar frequency in the
critically ill patient population as well. These factors, and
others, will need to be more clearly defined in order to
determine each patient's individual risk of DVT/PE and
potential benefit or harm gained from the use of rhAPC.
In conclusion, this is the first known case report of a radi-
ographically documented PE occurring in a patient receiv-
ing continuous infusion of rhAPC. This case suggests that
rhAPC alone may not be sufficient DVT/PE prophylaxis in
high risk patients. The risks associated with concomitant
anticoagulation and rhAPC therapy are unknown. Further
research is necessary to determine the safest and most
effective regimen for DVT/PE prophylaxis in patients
receiving rhAPC.
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